Compare L3Harris Technologies Inc (LHX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? L3Harris Technologies Inc trades at $280.5 (market cap $52.27B), while State Street SPDR S&P Biotech ETF trades at $151.8. The key difference: L3Harris Technologies Inc pays a 1.78% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, L3Harris Technologies Inc nearer its low. Which is the better fit depends on your goals.
| LHX | XBI | |
|---|---|---|
Market Cap | $52.27B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $378.48 | $164.28 |
52-Week Low | $263.09 | $85.16 |
Enterprise Value | $63.03B | — |
Dividend Yield | 1.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $280.57, down 0.51% today, with a bearish technical signal but strong fundamentals. The company reported Q1 2026 EPS of $2.72, beating estimates, and maintains robust cash flow. Recent contracts include a U.S. Space Force satellite deal and U.S. Army radio orders, supporting growth. Valuation metrics show a P/E of 30.62 and P/S of 2.36, with revenue rising to $21.87B in 2025.
Outlook is positive with a consensus price target of $367.50, implying 31% upside, driven by defense spending and execution. Risks include debt levels and geopolitical volatility. Analysts are 75% buy-rated, but technical indicators suggest near-term caution amid bearish moving averages.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
